
Journal Menu
► ▼ Journal Menu-
- Vaccines Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
10 July 2025
Vaccines | Section Restructuring
The journal Vaccines (ISSN: 2076-393X) is organized into topical Sections focusing on specific research areas within vaccine research, utilization, and immunization. Under the guidance of Editor-in-Chief Prof. Dr. Ralph A. Tripp and the Section Editors-in-Chief, the journal has decided to reorganize its topical sections to enhance navigation for authors and readers. The table below outlines both the original and the new section structures.
Original Sections | New Sections | |
1. | “Vaccines against Infectious Diseases” | “Vaccines against Tropical and Other Infectious Diseases” |
2. | “Vaccines against Tropical and Other Infectious Diseases” | “Vaccination Against Cancer and Chronic Diseases” |
3. | “Therapeutic Vaccines and Antibody Therapeutics” | “Influenza Virus Vaccines” |
4. | “Cancer Vaccines and Immunotherapy” | “HIV Vaccines” |
5. | “Influenza Virus Vaccines” | “Human Papillomavirus Vaccines” |
6. | “HIV Vaccines” | “Hepatitis Virus Vaccines” |
7. | “Human Papillomavirus Vaccines” | “COVID-19 Vaccines and Vaccination” |
8. | “Hepatitis Virus Vaccines” | “Veterinary Vaccines” |
9. | “COVID-19 Vaccines and Vaccination” | “Epidemiology and Vaccination” |
10. | “Veterinary Vaccines” | “Vaccines and Public Health” |
11. | “Epidemiology” | “Vaccine Design, Development, and Delivery” |
12. | “Human Vaccines and Public Health” | “Vaccines, Clinical Advancement, and Associated Immunology” |
13. | “Vaccine Adjuvants” | “Pathogens-Host Immune Boundaries” |
14. | “Attenuated/Inactivated/Live and Vectored Vaccines” | “Vaccine Advancement, Efficacy and Safety” |
15. | “Innate and Adaptive Immunity in Vaccination” | “Nucleic Acid (DNA and mRNA) Vaccines” |
16. | “Clinical Immunology” | |
17. | “Cellular/Molecular Immunology” | |
18. | “Pathogens-host Immune Interface” | |
19. | “Vaccination Optimization” | |
20. | “Vaccine Efficacy and Safety” | |
21. | “DNA and mRNA Vaccines” |
For more detailed information, please visit the following link: https://www.mdpi.com/journal/vaccines/sections. The Special Issues and their respective publications in the original Sections will be transferred to the new Sections.
Vaccines Editorial Office
4 July 2025
MDPI’s Newly Launched Journals in June 2025
Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.
We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.
Please feel free to browse and discover more about the new journals below.
Journal | Founding Editor-in-Chief | Journal Topics (Selected) |
![]() |
Prof. Dr. Chang-Pu Sun, China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China Editorial | View inaugural issue |
quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods View journal scope | Submit an article |
![]() |
Prof. Dr. Hualiang Lin, Sun Yat-sen University, China; Prof. Dr. Jose L. Domingo, Universitat Rovira i Virgili, Spain Editorial | View inaugural issue |
green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health | View journal scope | Submit an article |
![]() |
Prof. Dr. Francesco Veglio, University of L’Aquila, Italy Editorial | View inaugural issue |
ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies View journal scope | Submit an article |
![]() |
Prof. Dr. Junxing Zheng, Huazhong University of Science and Technology, China Editorial | View inaugural issue |
computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management View journal scope | Submit an article |
![]() |
Prof. Dr. Assunta Di Vaio, University of Naples Parthenope, Italy Editorial | View inaugural issue |
sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure View journal scope | Submit an article |
![]() |
Prof. Dr. Changjun Liu, Sichuan University, China Editorial | View inaugural issue |
bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication View journal scope | Submit an article |
2 July 2025
Meet Us at the 8th International Conference on Prevention & Infection Control, 16–19 September 2025, Geneva, Switzerland

Conference: The 8th International Conference on Prevention & Infection Control
Date: 16–19 September 2025
Location: Geneva, Switzerland
MDPI will be attending the 8th International Conference on Prevention & Infection Control (ICPIC), which will be held between 16 and 19 September 2025, as an exhibitor. We welcome researchers from various backgrounds to visit our booth and share their latest ideas with us.
ICPIC stands as the premier gathering for the global infection prevention and control (IPC) community, dedicated to advancing the field through cutting-edge research, innovative solutions, and the exchange of invaluable experiences. Our mission remains steadfast: to prevent healthcare-associated infections and control antimicrobial resistance, in addition to improving patient and healthcare worker safety worldwide. This year, our conference will delve into an array of crucial topics, including hand hygiene, artificial intelligence (AI)/machine learning, antibiotic stewardship, surgical site infection prevention, new techniques and approaches in environmental hygiene, environmental responsibility and eco-friendly solutions in IPC, and diagnostic as well as clinical microbiology challenges for IPC.
We eagerly anticipate your participation at the conference and look forward to welcoming you to Geneva. Please mark your calendars and prepare for an inspiring and enriching event.
The following MDPI journals will be represented at the conference:
- IJERPH;
- Pathogens;
- Infectious Disease Reports;
- Medical Sciences;
- Epidemiologia;
- Antibiotics;
- Diagnostics;
- Bacteria;
- Vaccines;
- Diseases;
- TropicalMed;
- COVID;
- Pharmacoepidemiology.
If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have. For more information, please visit https://conference.icpic.com/.
2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI’s 2024 Impact Factor Highlights
For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.
While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.
“These results reflect the trust that the scholarly community places in MDPI”
MDPI’s 2024 Impact Factor Highlights
- 298 MDPI journals received a Journal Impact Factor.
- 60 journals earned their first-ever Impact Factor
- To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
- Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
- 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
- What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
- 116 of our previously ranked journals increased their Impact Factor.
- 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.
These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.
Open Access with Impact
As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.
Further Reading
If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.
You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.
Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.
Impactful Research
MDPI Journals See Continued Growth in 2024 CiteScore Results
Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.
2024 Highlights:
- 322 MDPI journals received a CiteScore (up from 274 last year).
- 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
- 237 journals (85%) saw an increase in their CiteScore compared to last year.
- 48 journals received a CiteScore for the first time.
- 39 journals are now placed in the top 10% of their subject areas.
“This growth highlights our commitment to supporting open, trusted science”
What is CiteScore and how is it measured?
CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.
Why is this important?
These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.
Inside MDPI
Highlights from the MDPI USA Summit in Boston (5–6 June)
With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.
Why do we organize MDPI Summits?
These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:
- Share MDPI’s values, achievements, editorial practices, and local market collaborations.
- Collect feedback on MDPI operations and journal practices.
- Empower Chief Editors to confidently represent MDPI beyond the Summit.
While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.
|
|
|
About the Boston Summit
Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.
Agenda Highlights:
Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:
- MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
- AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
- MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
- Panel Discussion – Stefan, Feichi, Giulia, Claudia
- Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
- Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)
|
|
|
|
|
|
MDPI & the USA: Facts and Figures
- With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
- In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
- As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
- As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
- Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
- MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.
A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.
Coming Together for Science
Highlights from the MDPI France Summit in Paris (12–13 June)
We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.
|
|
|
Why a France Summit?
We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.
“Our authors and editors very much enjoy working with us”
Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:
This is not accurate.
A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.
The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.
Summit Overview
Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.
Summit Feedback
The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:
- “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
- “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
- “Very well organized! A great opportunity to see all French MDPI partners and editors.”
Program Highlights:
Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:
- MDPI Overview and France Collaboration – Stefan Tochev (CEO)
- MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
- Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
- AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
- Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
- Closing Remarks – Stefan Tochev
- Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan
|
|
|
|
|
|
MDPI & France: Facts and Figures
- With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
- As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
- As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
- Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
- In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.
Special thanks to our colleagues from Romanian offices for organizing this successful event.
Closing Thoughts
Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award
As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.
I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.
A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.
About the Tu Youyou Award For further information about the award and the winners, please visit the Tu Youyou Award website. |
Chief Executive Officer
MDPI AG
28 June 2025
Meet Us at the 17th Academic Conference of the Chinese Pharmacological Society, 22–26 July 2025, Xiong An, China

Conference: The 17th Academic Conference of the Chinese Pharmacological Society
Date: 22–26 July 2025
Location: Xiong An, China
MDPI will be attending the 17th Academic Conference of the Chinese Pharmacological Society as an exhibitor, which will be held from 22 to 26 July 2025. We welcome researchers from diverse backgrounds to attend and share their latest ideas with us.
The year 2025 marks the 40th anniversary of the establishment of the Chinese Pharmacological Society. We are pleased to attend the conference, which will systematically summarize the experience of the Chinese Pharmacological Society’s construction and development over the past 40 years. The 17th Academic Conference of the Chinese Pharmacological Society serves as an interdisciplinary forum for the prompt exchange of recent achievements, experiences, theories, technologies, and methods in China's pharmacology research domain, in addition to new drug development and related fields, The conference will promote the innovative development of China's pharmacology research and new drug development on a longer-term basis. Your participation will significantly contribute to the medical discourse and enhance the conference’s impact within the pharmacological field.
The following MDPI journals will be represented at the conference:
- Biomedicines;
- Future Pharmacology;
- Pharmacy;
- Immuno;
- Marine Drugs;
- Pharmaceutics;
- Pharmacoepidemiology;
- Vaccines;
- JPBI.
If you are planning to attend the above conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have. For more information about the conference, please visit the following website: https://mm.sciconf.cn/cn/web/index/29613?pc=1.
26 June 2025
Vaccines | Notable Papers Published in 2024 in the “Epidemiology” Section
1. “Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy”
by Andrea Ceccarelli, Federica Tamarri, Raffaella Angelini, Elizabeth Bakken, Ilaria Concari, Elsa Giannoccaro, Giada Domeniconi, Michela Morri, Chiara Reali, Francesca Righi et al.
Vaccines 2024, 12(1), 51; https://doi.org/10.3390/vaccines12010051
Full text available online: https://www.mdpi.com/2076-393X/12/1/51
2. “Sustaining the Elimination of Measles, Rubella and Congenital Rubella Syndrome in the Americas, 2019–2023: From Challenges to Opportunities”
by Gloria Rey-Benito, Desirée Pastor, Alvaro Whittembury, Regina Durón, Carmelita Pacis-Tirso, Pamela Bravo-Alcántara, Claudia Ortiz and Jon Andrus
Vaccines 2024, 12(6), 690; https://doi.org/10.3390/vaccines12060690
Full text available online: https://www.mdpi.com/2076-393X/12/6/690
3. “Possible Paths to Measles Eradication: Conceptual Frameworks, Strategies, and Tactics”
by Amy K. Winter and William J. Moss
Vaccines 2024, 12(7), 814; https://doi.org/10.3390/vaccines12070814
Full text available online: https://www.mdpi.com/2076-393X/12/7/814
4. “Congenital Rubella Syndrome Does Not Increase with Introduction of Rubella-Containing Vaccine”
by Kurt Frey
Vaccines 2024, 12(7), 811; https://doi.org/10.3390/vaccines12070811
Full text available online: https://www.mdpi.com/2076-393X/12/7/811
5. “The Global Measles and Rubella Laboratory Network Supports High-Quality Surveillance”
by Paul A. Rota, Roger Evans, Myriam Corinne Ben Mamou, Gloria Rey-Benito, Lucky Sangal, Annick Dosseh, Amany Ghoniem, Charles R. Byabamazima, Maurice Demanou, Raydel Anderson et al.
Vaccines 2024, 12(8), 946; https://doi.org/10.3390/vaccines12080946
Full text available online: https://www.mdpi.com/2076-393X/12/8/946
6. “An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity”
by Emma Chang-Rabley, Menno C. van Zelm, Emily E. Ricotta and Emily S. J. Edwards
Vaccines 2024, 12(6), 675; https://doi.org/10.3390/vaccines12060675
Full text available online: https://www.mdpi.com/2076-393X/12/6/675
7. “Assessment of Epidemiological Trend of Influenza-Like Illness in Italy from 2010/2011 to 2023/2024 Season: Key Points to Optimize Future Vaccination Strategies against Influenza”
by Sara Boccalini and Angela Bechini
Vaccines 2024, 12(8), 841; https://doi.org/10.3390/vaccines12080841
Full text available online: https://www.mdpi.com/2076-393X/12/8/841
8. “Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data”
by Juana Claus, Thijs ten Doesschate, Esther Taks, Priya A. Debisarun, Gaby Smits, Rob van Binnendijk, Fiona van der Klis, Lilly M. Verhagen, Marien I. de Jonge, Marc J. M. Bonten et al.
Vaccines 2024, 12(6), 691; https://doi.org/10.3390/vaccines12060691
Full text available online: https://www.mdpi.com/2076-393X/12/6/691
9. “Measles and Rubella Diagnostic and Classification Challenges in Near- and Post-Elimination Countries”
by Thomas D. Filardo, Stephen N. Crooke, Bettina Bankamp, Kelley Raines, Adria D. Mathis, Tatiana M. Lanzieri, R. Suzanne Beard, Ludmila Perelygina, David E. Sugerman and Paul A. Rota
Vaccines 2024, 12(6), 697; https://doi.org/10.3390/vaccines12060697
Full text available online: https://www.mdpi.com/2076-393X/12/6/697
10. “Serosurveillance for Measles and Rubella”
by Allison M. Brady, Elina El-Badry, Eriko Padron-Regalado, Nicole A. Escudero González, Daniel L. Joo, Paul A. Rota and Stephen N. Crooke
Vaccines 2024, 12(7), 816; https://doi.org/10.3390/vaccines12070816
Full text available online: https://www.mdpi.com/2076-393X/12/7/816
26 June 2025
Vaccines Receives an Updated Impact Factor of 3.4

We are pleased to share that Vaccines (ISSN: 2076-393X) was awarded an updated Impact Factor of 3.4 in the 2024 Journal Citation Reports™ released by Clarivate™ in June 2025. Vaccines ranks in Q2 (85 out of 183) in the “Immunology” category and Q2 (75 out of 195) in the “Medicine, Research and Experimental” category. Vaccines ranks in the first quartile (Q1) in these two JCI-indexed subject areas.
The 2024 Journal Impact Factor is calculated by dividing the number of citations received in 2024 to all publications in the journal from 2022 and 2023 by the total number of citable publications from those same years.
To learn more, visit our journal statistics website for detailed metrics or check out our news article for general information.
The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.
26 June 2025
Vaccines Receives an Increased CiteScore of 9.9

We are pleased to share that Vaccines (ISSN: 2076-393X) has received an increased CiteScore of 9.9 in June 2025.
Vaccines’ CiteScore ranks as follows:
- Q1 (24 out of 275) in the “Pharmacology (medical)” category;
- Q1 (36 out of 357) in the “Infectious Diseases” category;
- Q1 (39 out of 321) in the “Pharmacology” category;
- Q1 (25 out of 156) in the “Drug Discovery” category;
- Q1 (47 out of 240) in the “Immunology” category.
You can find more statistics on our website.
The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance.
This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Vaccines and its growing impact in laboratory and clinical vaccine research, utilization and immunization.
26 June 2025
Meet Us at the 12th Congress on Trends in Medical Mycology (TIMM-12), 19–22 September 2025, Bilbao, Spain

Conference: 12th Congress on Trends in Medical Mycology (TIMM-12)
Date: 19–22 September 2025
Location: Bilbao, Spain
We are delighted to announce that MDPI will serve as an exhibitor at the 12th Congress on Trends in Medical Mycology (TIMM-12), taking place from 19 to 22 September 2025 in collaboration with the European Confederation of Medical Mycology (ECMM) and the Spanish Association of Mycology (AEM).
TIMM-12 will cover new, fascinating insights into the biology of fungi, intriguing host–fungal interactions, updated diagnostic and therapeutic management approaches, changing dynamics in clinical epidemiology, and the emergence of antifungal resistance and newly discovered fungal pathogens. The scientific topics are designed to be applicable from bench to bed for basic scientists in medical mycology, medical mycologists, microbiologists, and a wide range of clinicians specialized in adult or pediatric infectious diseases, hematology, oncology, transplantation medicine and primary immunodeficiencies, critical care, dermatology, and immunology and all others with an interest in medical mycology. TIMM-12 will be an excellent opportunity for all participants to meet face-to-face with old friends and colleagues, make new friends, and establish new collaborations in medical mycology.
Serving as both a sponsor and exhibitor underscores MDPI’s unwavering support for the dissemination of high-impact research in medical mycology. Our participation in TIMM-12 highlights our mission to accelerate open access knowledge exchange and facilitate global scientific collaboration. Researchers attending the conference will have the opportunity to engage with representatives from the following MDPI journals, all of which publish pioneering work covering fungal research and related disciplines:
The following open access journals will be represented at the conference:
- JoF;
- Microorganisms;
- Infectious Disease Reports;
- BioTech;
- Vaccines;
- Microbiology Research;
- Toxins;
- Taxonomy;
- Acta Microbiologica Hellenica.
We cordially invite all attendees to visit our exhibition booth to discuss potential collaborations, explore publishing opportunities, and learn more about our open access initiatives. Our delegates are eager to meet you, address your inquiries, and support your contributions to the field.
For further details about TIMM-12, please visit the official conference website: https://www.timm2025.org/.
17 June 2025
Meet Us at the 29th Annual Meeting of the Japanese Society of Travel and Health, 19–20 July 2025, Nara, Japan

Conference: The 29th Annual Meeting of the Japanese Society of Travel and Health
Organization: Japanese Society of Travel and Health
Date: 19–20 July 2025
Place: Nara, Japan
Representatives from a number of MDPI journals will be attending the 29th Annual Meeting of the Japanese Society of Travel and Health as exhibitors. The meeting will be held in Nara, Japan, from 19 to 20 July 2025.
The Japanese Society of Travel and Health (JSTH), established in 1997, has been dedicated to advancing the field of travel medicine. The 29th Annual Conference, themed “Let's learn together and create together: a new era of Travel and Health that illuminates future travel”, will focus on the following key topics:
- Infectious disease treatment, infection control, and vaccines;
- Mental health, chronic disease management, and medical insurance;
- Establishment and operations of travel clinics;
- Latest trends, including digital transformation and AI.
As an interdisciplinary platform, this conference will bring physicians, nurses, pharmacists, and travel industry experts together to discuss the most pressing global health challenges.
The following MDPI journals will be represented at the conference:
- Tropical Medicine and Infectious Disease;
- Infectious Disease Reports;
- IJERPH;
- Diseases;
- COVID;
- JPBI;
- Vaccines.
If you are planning to attend the conference above, please feel free to visit our booth. Our delegates look forward to meeting you in person and to answering any questions you may have. For more information about the conference, please visit the following website: https://www.c-linkage.co.jp/jsth29/.